Abstract: Described herein are compositions comprising, and methods for using, biocompatible cold slurries and methods of administering the same to provide reversible inhibition of peripheral nerves in a subject in need thereof.

Abstract: One aspect of the invention provides a slurry comprising: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible surfactant. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; a biocompatible surfactant; and a foam comprising a plurality of gas bubbles. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible excipient. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a lipolytic agent.

Abstract: Slurries comprise liquid water, about 2% to about 70% ice by volume, and one or more additives affecting flowability and/or tonicity of the slurry. Solutions for making a slurry comprise liquid water and one or more additives affecting flowability of the slurry. Flowability of the slurry relates to ice particles capable of flowing through a cannula, such as a needle. The slurry is suitable for injection into subcutaneous fat of a human subject for removal of adipose tissue.

Abstract: Described herein are compositions comprising, and methods for using, biocompatible cold slurries and methods of administering the same to provide reversible inhibition of peripheral nerves in a subject in need thereof.

Abstract: Described herein are compositions comprising, and methods for using, biocompatible cold slurries and methods of administering the same to provide reversible inhibition of peripheral nerves in a subject in need thereof.

Abstract: The present disclosure provides systems and method for medical ice slurry production. In particular, systems and methods are provided for medical ice slurry production that enable an end user to produce and deliver a sterile medical ice slurry at the point of care.

Abstract: A method for treating vascular diseases is provided. The method includes fabricating a sterile ice slurry including water and ice particles, cooling the sterile ice slurry to a predetermined temperature, and injecting the sterile ice slurry into a desired tissue region. The desired tissue region includes perivascular adipose tissue.

Abstract: Compositions, systems and methods are provided for the treatment of subcutaneous brown or beige fat or visceral brown or beige fat, wherein the compositions comprise a cold solution comprising liquid water and/or ice particles, and optionally one or more additives and/or pharmacologic agents. The treatment of subcutaneous or visceral brown or beige fat provides activation of brown adipocytes, proliferation of brown adipocytes, increased volume of brown adipocytes, differentiation of precursors into beige and/or brown adipocytes, activation of beige adipocytes, stimulation of beige adipocytes and/or cryolipolysis of white adipocytes. The methods of treatment result in increased metabolic health, weight loss, and improved health.

Abstract: The present invention provides a cold solution and method for treating obstructive sleep apnea. The cold solution can comprise liquid and/or solid ice particles. In one embodiment, the method comprises delivering a cold solution to target tissue where the target tissue can be fat tissue located in one or more of an airway, a neck, a thorax, a diaphragm, a face, or an abdomen.

Abstract: A substantially solid solution is provided, which includes water and optionally one or more additives, wherein about 71% to about 100% of the water by volume is in a solid state. The substantially solid solution may be administered to a subcutaneous fat layer of a subject, in order to reduce or remove adipocytes through freezing. The substantially solid solution may be generated in a mold, or at a point of delivery, and may be administered by any suitable device or administered directly to a treatment site via an incision.

Abstract: The present disclosure provides systems and method for medical ice slurry production. In particular, systems and methods are provided for medical ice slurry production that enable an end user to produce and deliver a sterile medical ice slurry at the point of care.

Abstract: The present invention provides a cold solution and method for inducing therapeutic hypothermia. The cold solution can comprise liquid and/or solid ice particles.

Abstract: Systems and methods for the use of cooling to trigger desirable effects of increased vasculature and/or development of new collagen in biological tissue are provided. In particular, the systems and methods provide a cooling treatment system configured to provide bulk or fractionated cooling at either at ablative temperatures or intermediary remodeling temperatures to promote tissue remodeling by inducing increased vasculature and/or the formation of new collagen.

Abstract: A method for treating vascular diseases is provided. The method includes fabricating a sterile ice slurry including water and ice particles, cooling the sterile ice slurry to a predetermined temperature, and injecting the sterile ice slurry into a desired tissue region. The desired tissue region includes perivascular adipose tissue.

Abstract: A slurry is injected into a subject at a treatment site selected from the group consisting of (i) a deep subcutaneous fat layer, (ii) a superficial subcutaneous fat layer, and (iii) the deep subcutaneous fat layer and the superficial subcutaneous fat layer. Fat cells in the selected treatment site are ablated by the slurry. For example, the slurry is injected into (i) the deep subcutaneous fat layer only, (ii) the superficial subcutaneous fat layer only, (iii) the deep subcutaneous fat layer followed by the superficial subcutaneous fat layer, (iv) the superficial subcutaneous fat layer followed by the deep subcutaneous fat layer, or (v) the deep subcutaneous fat layer and the superficial subcutaneous fat layer simultaneously.

Abstract: Slurries comprise liquid water, about 2% to about 70% ice by volume, and one or more additives affecting flowability and/or tonicity of the slurry. Solutions for making a slurry comprise liquid water and one or more additives affecting flowability of the slurry. Flowability of the slurry relates to ice particles capable of flowing through a cannula, such as a needle. The slurry is suitable for injection into subcutaneous fat of a human subject for removal of adipose tissue.

Abstract: One aspect of the invention provides a slurry comprising: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible surfactant. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; a biocompatible surfactant; and a foam comprising a plurality of gas bubbles. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible excipient. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a lipolytic agent.

Abstract: Described herein are compositions comprising, and methods for using, biocompatible cold slurries and methods of administering the same to provide reversible inhibition of peripheral nerves in a subject in need thereof.

Abstract: A confection may include one or more skin protective ingredients, a thickening agent, and a sweetening agent. The one or more skin protective ingredients may include Polypodium leucotomos extract, astaxanthin, Pinus pinaster, lycopene, lutein, and/or zeaxanthin. In some embodiments, the confection may be formulated as a gummy, chewable, or candy, and may be taken orally on a regular basis (e.g., daily) to treat and/or prevent one or more skin conditions.

Abstract: Systems and methods for the use of cooling to trigger desirable effects of increased vasculature and/or development of new collagen in biological tissue are provided. In particular, the systems and methods provide a cooling treatment system configured to provide bulk or fractionated cooling at either at ablative temperatures or intermediary remodeling temperatures to promote tissue remodeling by inducing increased vasculature and/or the formation of new collagen.